Pharmaceutical companies speed up the layout of product lines, and the industrial chain extends into the general trend

[pharmaceutical network industry trends] products are the powerful weapon of enterprise competition and the core of marketing Product line planning is the basic guarantee of sustainable development and rapid development of enterprises and the guarantee and necessity of marketing management With the overall promotion of the "4 + 7" volume procurement, two vote system and other pharmaceutical market reform policies, some domestic pharmaceutical enterprises have begun to actively adjust the company's product layout and enrich product lines to adapt to policy and market changes For example, Hengrui pharmaceutical, which started with generic drugs and occupied the leading position in the industry, has been increasing the research and development of innovative drugs since 2018 According to the 2018 annual report, the company has invested 2.67 billion yuan in research and development in 2018, accounting for 15.33% of its sales revenue in that year; in 2019, the investment in research and development will exceed 3 billion yuan At present, there are dozens of innovative drugs under research in the pipeline, and five of them have been approved On November 7, Hengrui pharmaceutical announced that it plans to introduce the drug cyclasol, which is used to treat dry eye disease by novaliq in Germany, with a price of no more than 1.16 billion yuan Gamma (0.1% cyclosporine a preparation) and nov03 (perfluorohexyl octane), after the completion of the transaction, Hengrui will obtain the rights of clinical development, production and marketing of these two products in China At present, the biosimilar drug of Fosun, rituximab, hanlikang, has been put on the market, and the applications for listing Adamu and trastuzumab have been accepted It can be predicted that in the future, it will gradually enter the harvest period of innovative drugs, and the net profit will resume growth By the end of 2018, there are 15 small molecule innovative drugs, 10 biological innovative drugs and 17 biological similar drugs under research Many products have been in clinical stage, and the product echelon has been relatively rich, which will guarantee the long-term development of the company Not long ago, AoHong Pharmaceutical Co., Ltd., a subsidiary of AoHong Pharmaceutical Co., Ltd., planned to acquire about 75.9% of Liszt pharmaceutical shares held by SDIC hi tech through public bidding with no more than 590 million yuan Under the condition of completion of the transaction, ohong pharmaceutical will be able to transfer the intellectual property rights and other related rights of the main product penehyclidine hydrochloride injection (changtonin) owned by Horgos Yuyue, as well as the products under research "et-26" and "pentazoxine hydrochloride" with 84.99 million yuan The incorporation of the three products will further enrich the product line in the field of Fosun medical operation period Recently, Longjin pharmaceutical also announced that the company has signed an agreement on equity transfer, capital increase and share expansion with Yunnan Muya and its existing shareholders, and determined to acquire 51% of the equity of Yunnan Muya with 15 million yuan, so as to realize the holding of the company According to the announcement, the main business of Yunnan Muya is the large-scale cultivation of industrial marijuana In 2016, it obtained the industrial marijuana cultivation license of Yunnan Province, completed the renewal of the license on April 20, 2018, and approved the cultivation of industrial marijuana area of 12000 mu After Longjin pharmaceutical acquired Yunnan Muya, it is expected that the planting area of industrial marijuana will exceed 10000 mu in 2019, which is expected to achieve the promised profit target There are also two good varieties of atorvastatin calcium tablets in Xing'an pharmaceutical industry: simvastatin dropping pills and loxoprofen sodium tablets, which are used to treat hyperlipidemia After the acquisition, its main products, atorvastatin calcium tablets (hyperlipidemia drugs for cardiovascular disease prevention), will be added to the product portfolio of Dongrui pharmaceutical, enriching its product line Dongrui pharmaceutical will use the sales network and resources to promote the target group's drug products, with a view to producing synergy and improving the comprehensive competitiveness of Dongrui group Under the influence of new policy environment, new product listing, new international competition situation and other factors, both domestic and foreign pharmaceutical enterprises are bound to adjust their product strategic direction according to external and internal factors Therefore, in addition to the above-mentioned enterprises, a number of pharmaceutical enterprises have issued acquisition announcements since this year Some of them have purchased products and some have purchased land, all of which are aimed at promoting the industrial chain extension layout, enhancing the productivity and market competitiveness of enterprises In the future, this kind of inter enterprise acquisition is expected to continue.